louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05088252: Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection
Official title: Effects of Desflurane on the Quality of Anesthesia Recovery Period in Patients Undergoing Endonasal Endoscopic Pituitary Adenoma Resection#a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pituitary Neoplasms
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2021-10-21
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into the trachea after the operation. GH-secreting pituitary adenoma causes pharyngeal soft tissue and tongue hypertrophy. These conditions increase the risk of respiratory obstruction and hypoxemia during anesthesia recovery. Propofol total intravenous anesthesia has a rapid effect and a low incidence of nausea and vomiting. Patients anesthetized with desflurane recover quickly is conducive to early recovery of respiratory function and orientation. This study intends to compare the effects of desflurane and propofol on the quality of anesthesia recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.


Eligibility criteria: Inclusion Criteria:

* 18-65 years;
* Elective endoscopic transsphenoidal resection of pituitary adenomas;
* ASA status I-III;
* Informed consent signed by patients.

Exclusion Criteria:

* emergency surgery;
* complicated with cerebrovascular disease;
* complicated with pulmonary disease, oxygen saturation below 95% without oxygen;
* expected to retain endotracheal intubation;
* preoperative disturbance of consciousness was not compatible with assessment;
* complicated with primary hypothyroidism;
* previous history of cervical surgery, burns, and radiotherapy;
* BMI \>30kg/m2;
* invasive pituitary adenoma with Knosp grade 4.

Primary outcomes:
measure: Time required of the Aldrete score reached 9 points after drug withdrawal.
timeFrame: immediately after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Ruquan Han
state: Beijing
Study officials:
References:
Clinical trial NCT06198452: Vision Improvement for Patients With Age-Related Macular Degeneration
Official title: Vision Improvement for Patients With Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Macular Degeneration
Lead sponsor: VIS, Inc.
Sponsor class: INDUSTRY
First posted: 2024-01-10
Enrollment: 200
Sex: ALL
Minimum age (years): 50
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective cohort study
Primary purpose: TREATMENT

Brief summary: This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Detailed description: This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Eligibility criteria: Inclusion Criteria:

Subjects who meet all of the following criteria are candidates for this study:

1. Male or Female
2. Any race
3. Patient is at least 50 years old.
4. Patient has diagnosed end stage dry or wet age-related macular degeneration in one or both eyes, as verified by a complete ocular examination.
5. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.
6. Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D in eye(s) to be treated.
7. Patient has moderate to severe vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/80 or worse (decimal less than or equal to 0.25; logMAR ≥ 0.60).in the better eye.
8. Patient has CDVA of 20/400 or better (decimal greater than or equal to 0.05; logMAR ≤ 1.30) in the worse eye.
9. Patient is not a contact lens (CL) wearer.
10. Patient is willing and able to comply with all examinations.
11. Patient must be competent to sign an informed consent form before study entry.

Exclusion Criteria:

Subjects who meet any of the following criteria are to be excluded from this study:

1. Corneal disease or corneal disorder in either eye.
2. Pathological retinal morphology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola.
3. Gonzalez-Markowitz chart Potential Visual Acuity (PVA) in the eye to be treated that is not improved by at least four lines compared to CDVA;
4. Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma;
5. Previous corneal surgery in the eye to be treated; and
6. Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.

Primary outcomes:
measure: Visual Acuity
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04186832: Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
Official title: Feasibility of Monitoring Step Count as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Patients Undergoing Radiation Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Glioma
Radiation Therapy Patient
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2019-12-05
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This trial studies the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy. Physical activity measured by step count may help to improve the quality of life and symptoms for patients with newly diagnosed glioma.

Detailed description: PRIMARY OBJECTIVE:

I. Evaluate the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy (RT) at MD Anderson Cancer Center (MDACC).

SECONDARY OBJECTIVE:

I. Estimate the effects of physical activity as measured by step count on cognition, fatigue, anxiety and depression scores and assess differences between groups.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients wear a pedometer for step count monitoring over 6 weeks.

GROUP II: Patients wear a FitBit for step count monitoring over 6 weeks.

After completion of study, patients are followed up at 3 and 6 months after completing radiation therapy.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with a glioma and going to receive at least 4 weeks of RT at MDACC at the Texas Medical Center campus with at least 20 fractions
* Karnofsky performance status (KPS) of 70 or above
* Wearable activity tracker (WAT) - naive
* Able to read and speak English
* Able to provide informed consent
* Access to a smartphone
* Access to Wi-Fi

Exclusion Criteria:

* Cognitive and/or major sensory deficits that would impede the completion of assessment instruments as deemed by the clinical team

Primary outcomes:
measure: Consent rate
timeFrame: Up to 6 months after completing radiation therapy
measure: Fitbit adherence rate
timeFrame: Up to 6 weeks
measure: Retention rate
timeFrame: Up to 6 months
measure: Satisfaction/acceptability rate questionnaire
timeFrame: Up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Shiao-Pei S Weathers
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04909632: Tongue Fur and Metabolites in Diabetes Mellitus
Official title: Correlation Between Tongue Fur and Metabolites in Diabetes Mellitus and pre-diabetes-a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Pre-diabetes
Keywords: diabetic mellitus , tongue fur, metabolites, and biomarkers
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2021-06-02
Enrollment: 160
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is a prospective cross-sectional study. The investigators enroll participants form the department of endocrinology and of metabolism, China Medical University Hospital. In total, 300 participants , composed of 100 of type 2 diabetes , 100 of pre-DM and 100 healthy participants. The investigators apply tongue diagnosis system, pulse wave analysis, body constitution questionnaires, and nailfold capillaroscopy to assess the differences of TCM diagnosis. After collecting the tongue coating and analyzing the metabolite signals with a flying mass spectrometer, The investigators collect the data to establish metabolite pattern and biomarkers.

This study aims to identify the clinical symptoms of DM with TCM diagnostic tools and investigate the pattern difference and treatment for DM. Furtherly, the investigators add mass spectrometer to analyze the metabolites of tongue coating, the investigators propose to establish a metabolite pattern and biomarker to identify important biological indicators of DM.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of type 2 DM
2. Clinical diagnosis of pre-DM
3. Participants in the control group had a normal fasting glucose level

Exclusion Criteria:

1. comorbidity of inadequate heart, liver, kidney, or other serious diseases.
2. pregnancy or lactation.
3. history of mental illness.

Primary outcomes:
measure: The differentiation of tongue features mellitus and pre-diabetes
timeFrame: 2 years
Secondary outcomes:
measure: The tongue coating metabolic markers in patients with diabetes
timeFrame: 2 years
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
affiliation: China Medical University, China
name: Lun-Chien Lo
role: STUDY_DIRECTOR
References:
Clinical trial NCT01027832: Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)
Official title: Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Tracheobronchitis
Keywords: tracheobronchitis
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-12-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mechanically Ventilated patients in the intensive care unit (ICU) often present with fever, and purulent sputum, but without radiological evidence of pneumonia.

These patients may have tracheobronchitis. Some suspect that this condition precedes the development of pneumonia. Antibiotic treatment in tracheobronchitis is controversial.

The investigators will recruit patients with tracheobronchitis and randomize them into 2 groups. One group will be treated with antibiotics and the other group will serve as control.

Detailed description: Patients with proved tracheobronchitis who are mechanically ventilated for more than 48 hrs, will undergo a CT scan to rool our pneumonia that may not be seen on a routine chest x-ray.

After ruling out pneumonia by CT scan, patients will be randomized into 2 groups. Intervention group will receive 7 days of treatment with Piperacillin/Tazobactam. A control group will receive nothing.

Primary endpoint wil be the rate of new pneumonias and secondary endpoint will be ICU Length of stay, days on mechanical ventilation and 28 day mortality.

Eligibility criteria: Inclusion Criteria:

* Tracheobronchitis as defined by:

  * Purulent sputum with \> 10 x 4 CFU
  * Leukocytosis or leukopenia
  * Fever
  * No pneumonia on CT scan

Exclusion Criteria:

* Recent treatment of pneumonia
* Abnormal Chest X-ray
* Evidence of Pneumonia on CT scan

Primary outcomes:
measure: Rate of development of new pneumonia
timeFrame: 2 years
Secondary outcomes:
measure: ICU length of stay (LOS) and mortality
timeFrame: 2 years
Other outcomes:
Locations:
city: Beer Yakov
country: Israel
facility: Assaf Harofe MC
state: Zerifin
Study officials:
affiliation: Tel Aviv University, Faculty of Medicine, Israel.
name: Arie Soroksky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00403832: Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients
Official title: Comparison of Two Different Acrylate Intraocular Lenses in Cataract Surgery in Patients With Non-infectious Uveitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uveitis
Cataract
Lead sponsor: St. Franziskus Hospital
Sponsor class: OTHER
First posted: 2006-11-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cataract is a common complication in uveitis patients. Cataract operations with intraocular lens implantation are difficult in these patients because of complication due to the biocompatibility of the intraocular lens. In this study, uveal and capsular biocompatibility of two widely used acrylate intraocular lenses are compared.


Eligibility criteria: Inclusion Criteria:

* non infectious uveitis
* no active inflammation
* significant visual disturbance related to lens opacification

Exclusion Criteria:

* vitreous opacification
* ocular hypertension/glaucoma

Primary outcomes:
measure: visual acuity
measure: cell deposits on anterior IOL surface
measure: posterior capsular opacification
Secondary outcomes:
Other outcomes:
Locations:
city: Münster
country: Germany
facility: Department of Ophthalmology at St.-Franziskus Hospital
Study officials:
affiliation: Department of Ophthalmology at St.-FranziskusHospital Münster
name: Arnd Heiligenhaus, Md Phd
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roesel M, Heinz C, Koch JM, Heiligenhaus A. Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):715-20. doi: 10.1007/s00417-009-1269-1. Epub 2010 Jan 16.
Clinical trial NCT00604032: Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%
Official title: Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Safety when exposed to sunlight
Lead sponsor: Coria Laboratories, Ltd.
Sponsor class: INDUSTRY
First posted: 2008-01-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.


Eligibility criteria: Inclusion Criteria:

* Normal healthy volunteers
* 18 years of age or older

Exclusion Criteria:

* Less than 18 years of age

Primary outcomes:
measure: UV induced skin sensitization
timeFrame: 4 days
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Suncare Research Laboratories
state: North Carolina
Study officials:
affiliation: Suncare Laboratories
name: Joseph Stanfiled, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01334632: Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block
Official title: Comparison of Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block Versus Patient Controlled Analgesia Morphine
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Brachial Plexus Injury
Keywords: Electrophysiological study
Nerve block
Analgesia, patient-controlled
Shoulder surgery
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2011-04-13
Enrollment: 0
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Brachial plexus injury after shoulder surgery with continuous interscalene block is 2.4% at 1 month and 0% at 6 months, but may be higher with a systematic postoperative neurological examination. Indeed, femoral neuropathy after anterior cruciate ligament reconstruction is 24% at 6 weeks in a cohort of 20 consecutive patients systematically screened with an electromyogram. Brachial plexus injury may be the consequence of the surgery (direct lesion by traction) or the continuous interscalene block. The goal of this study is to define the etiology of this postoperative neuropathy.

Detailed description: Rotator cuff surgery is associated with moderate to severe postoperative pain. Among different analgesic strategies, continuous interscalene block is reported to be an efficient method, reducing opioid consumption and allowing rapid rehabilitation; however, patients may develop a transient neuropathy after surgery, which could have a significant impact on active patients. This study is designed to compare the incidence of brachial plexus injury in two groups of patients: one with a continuous interscalene block, and one with a patient control analgesia of morphine (self-iv administration of morphine). All patients will have a clinical neurological exam with a preoperative electromyogram in order to rule out a pre-existing neuropathy. Another clinical neurological exam with electromyogram will be performed between 4 and 6 postoperative weeks and, if pathological repeated at 6 months, 9 months and 12 months. The surgery will be done under general anesthesia for all patients.

Eligibility criteria: Inclusion Criteria:

* patients planned for rotator cuff repair
* ASA 1, 2 and 3
* age 16 years and more

Exclusion Criteria:

* peripheral neuropathy
* pre-existing brachial plexus injury
* diabetes mellitus
* alcoholism
* drug addiction

Primary outcomes:
measure: Incidence of brachial plexus injury
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Department of Anesthesia, Centre Hospitalier Universitaire Vaudois and University of Lausanne
state: Vaud
Study officials:
affiliation: Department of Anesthesia, Centre Hospitalier Universitaire Vaudois and University of Lausanne
name: Eric Albrecht, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06945432: Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
Official title: Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tumors
PET / CT
FDG PET/CT
FAPI
Lead sponsor: Lanzhou University Second Hospital
Sponsor class: OTHER
First posted: 2025-04-25
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Malignant tumor patients diagnosed by histopathology and imaging

Brief summary: The aim of this study is to compare the diagnostic efficacy of 68Ga-CTR-FAPI PET/CT and 18F-FDG PET/CT in various malignant tumors

Detailed description: This study recruited malignant tumor patients diagnosed by histopathology and imaging at the Nuclear Medicine Department of Lanzhou University Second Hospital from July 2024 to March 2025. The enrolled patients underwent 68Ga-CTR-FAPI PET/CT and 18F-FDG PET/CT scans within one week.

Eligibility criteria: Inclusion Criteria:

(a) Age ≥ 18 years old; (b) Suspected or newly diagnosed malignant tumors, evaluating the therapeutic effect of the tumor, or discovering recurrence/metastasis; (c) Obtain approval from oncologists and agree to undergo 18F-FDG and 68Ga-CTR-FAPI PET/CT scans within one week.

Exclusion Criteria:

(a) Pregnancy or lactation period; (b) Claustrophobia. (c) Serious health problems: such as severe heart, liver and kidney dysfunction, diseases that affect the metabolism or clearance of imaging agents.

Primary outcomes:
measure: Lesion uptake
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Lanzhou
country: China
facility: The Second Hospital of Lanzhou University
state: Gansu
Study officials:
References:
Clinical trial NCT01668732: Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts
Official title: Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heroin Addiction
Lead sponsor: National Health Research Institutes, Taiwan
Sponsor class: OTHER
First posted: 2012-08-20
Enrollment: 1
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community heroin addicts

Brief summary: Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task.

It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning.

Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.


Eligibility criteria: Inclusion Criteria:

* 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: National Health Research Institute, Taiwan
name: Sheng Chang Wang, M.D., M.Sc.
role: PRINCIPAL_INVESTIGATOR
References: